Request Free Sample ×
India Induced Pluripotent Stem Cells Market Research Report - Forecast To 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

India Induced Pluripotent Stem Cells Market

ID: MRFR/LS/50685-HCR
200 Pages
Nidhi Mandole
Last Updated: February 06, 2026

India Induced Pluripotent Stem Cells Market Research Report By Application (Regenerative Medicine, Drug Discovery, Disease Modeling, Toxicology Testing, Gene Therapy), By Cell Type (Cardiomyocytes, Neurons, Hepatocytes, Pancreatic Cells, Mesenchymal Stem Cells), By Source of Induction (Transcription Factors, Small Molecules, MicroRNA, Electroporation, Viral Vectors) and By End User (Pharmaceutical Companies, Research Institutes, Biotechnology Companies, Academic Institutions) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

India Induced Pluripotent Stem Cells Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Application (USD Million)
  49.     4.1.1 Regenerative Medicine
  50.     4.1.2 Drug Discovery
  51.     4.1.3 Disease Modeling
  52.     4.1.4 Toxicology Testing
  53.     4.1.5 Gene Therapy
  54.   4.2 Healthcare, BY Cell Type (USD Million)
  55.     4.2.1 Cardiomyocytes
  56.     4.2.2 Neurons
  57.     4.2.3 Hepatocytes
  58.     4.2.4 Pancreatic Cells
  59.     4.2.5 Mesenchymal Stem Cells
  60.   4.3 Healthcare, BY Source of Induction (USD Million)
  61.     4.3.1 Transcription Factors
  62.     4.3.2 Small Molecules
  63.     4.3.3 MicroRNA
  64.     4.3.4 Electroporation
  65.     4.3.5 Viral Vectors
  66.   4.4 Healthcare, BY End User (USD Million)
  67.     4.4.1 Pharmaceutical Companies
  68.     4.4.2 Research Institutes
  69.     4.4.3 Biotechnology Companies
  70.     4.4.4 Academic Institutions
  71. 5 SECTION V: COMPETITIVE ANALYSIS
  72.   5.1 Competitive Landscape
  73.     5.1.1 Overview
  74.     5.1.2 Competitive Analysis
  75.     5.1.3 Market share Analysis
  76.     5.1.4 Major Growth Strategy in the Healthcare
  77.     5.1.5 Competitive Benchmarking
  78.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  79.     5.1.7 Key developments and growth strategies
  80.       5.1.7.1 New Product Launch/Service Deployment
  81.       5.1.7.2 Merger & Acquisitions
  82.       5.1.7.3 Joint Ventures
  83.     5.1.8 Major Players Financial Matrix
  84.       5.1.8.1 Sales and Operating Income
  85.       5.1.8.2 Major Players R&D Expenditure. 2023
  86.   5.2 Company Profiles
  87.     5.2.1 Fujifilm Cellular Dynamics (JP)
  88.       5.2.1.1 Financial Overview
  89.       5.2.1.2 Products Offered
  90.       5.2.1.3 Key Developments
  91.       5.2.1.4 SWOT Analysis
  92.       5.2.1.5 Key Strategies
  93.     5.2.2 Astellas Pharma (JP)
  94.       5.2.2.1 Financial Overview
  95.       5.2.2.2 Products Offered
  96.       5.2.2.3 Key Developments
  97.       5.2.2.4 SWOT Analysis
  98.       5.2.2.5 Key Strategies
  99.     5.2.3 Takeda Pharmaceutical (JP)
  100.       5.2.3.1 Financial Overview
  101.       5.2.3.2 Products Offered
  102.       5.2.3.3 Key Developments
  103.       5.2.3.4 SWOT Analysis
  104.       5.2.3.5 Key Strategies
  105.     5.2.4 Roche Holding (CH)
  106.       5.2.4.1 Financial Overview
  107.       5.2.4.2 Products Offered
  108.       5.2.4.3 Key Developments
  109.       5.2.4.4 SWOT Analysis
  110.       5.2.4.5 Key Strategies
  111.     5.2.5 Lonza Group (CH)
  112.       5.2.5.1 Financial Overview
  113.       5.2.5.2 Products Offered
  114.       5.2.5.3 Key Developments
  115.       5.2.5.4 SWOT Analysis
  116.       5.2.5.5 Key Strategies
  117.     5.2.6 Thermo Fisher Scientific (US)
  118.       5.2.6.1 Financial Overview
  119.       5.2.6.2 Products Offered
  120.       5.2.6.3 Key Developments
  121.       5.2.6.4 SWOT Analysis
  122.       5.2.6.5 Key Strategies
  123.     5.2.7 Merck KGaA (DE)
  124.       5.2.7.1 Financial Overview
  125.       5.2.7.2 Products Offered
  126.       5.2.7.3 Key Developments
  127.       5.2.7.4 SWOT Analysis
  128.       5.2.7.5 Key Strategies
  129.     5.2.8 Cellectis (FR)
  130.       5.2.8.1 Financial Overview
  131.       5.2.8.2 Products Offered
  132.       5.2.8.3 Key Developments
  133.       5.2.8.4 SWOT Analysis
  134.       5.2.8.5 Key Strategies
  135.   5.3 Appendix
  136.     5.3.1 References
  137.     5.3.2 Related Reports
  138. 6 LIST OF FIGURES
  139.   6.1 MARKET SYNOPSIS
  140.   6.2 INDIA MARKET ANALYSIS BY APPLICATION
  141.   6.3 INDIA MARKET ANALYSIS BY CELL TYPE
  142.   6.4 INDIA MARKET ANALYSIS BY SOURCE OF INDUCTION
  143.   6.5 INDIA MARKET ANALYSIS BY END USER
  144.   6.6 KEY BUYING CRITERIA OF HEALTHCARE
  145.   6.7 RESEARCH PROCESS OF MRFR
  146.   6.8 DRO ANALYSIS OF HEALTHCARE
  147.   6.9 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  148.   6.10 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  149.   6.11 SUPPLY / VALUE CHAIN: HEALTHCARE
  150.   6.12 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
  151.   6.13 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
  152.   6.14 HEALTHCARE, BY CELL TYPE, 2024 (% SHARE)
  153.   6.15 HEALTHCARE, BY CELL TYPE, 2024 TO 2035 (USD Million)
  154.   6.16 HEALTHCARE, BY SOURCE OF INDUCTION, 2024 (% SHARE)
  155.   6.17 HEALTHCARE, BY SOURCE OF INDUCTION, 2024 TO 2035 (USD Million)
  156.   6.18 HEALTHCARE, BY END USER, 2024 (% SHARE)
  157.   6.19 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
  158.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  159. 7 LIST OF TABLES
  160.   7.1 LIST OF ASSUMPTIONS
  161.     7.1.1
  162.   7.2 India MARKET SIZE ESTIMATES; FORECAST
  163.     7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  164.     7.2.2 BY CELL TYPE, 2025-2035 (USD Million)
  165.     7.2.3 BY SOURCE OF INDUCTION, 2025-2035 (USD Million)
  166.     7.2.4 BY END USER, 2025-2035 (USD Million)
  167.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  168.     7.3.1
  169.   7.4 ACQUISITION/PARTNERSHIP
  170.     7.4.1

India Healthcare Market Segmentation

Healthcare By Application (USD Million, 2025-2035)

  • Regenerative Medicine
  • Drug Discovery
  • Disease Modeling
  • Toxicology Testing
  • Gene Therapy

Healthcare By Cell Type (USD Million, 2025-2035)

  • Cardiomyocytes
  • Neurons
  • Hepatocytes
  • Pancreatic Cells
  • Mesenchymal Stem Cells

Healthcare By Source of Induction (USD Million, 2025-2035)

  • Transcription Factors
  • Small Molecules
  • MicroRNA
  • Electroporation
  • Viral Vectors

Healthcare By End User (USD Million, 2025-2035)

  • Pharmaceutical Companies
  • Research Institutes
  • Biotechnology Companies
  • Academic Institutions

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓